There are several clinical trials currently underway to investigate potential treatments for PSP (progressive supranuclear palsy). PSP is a rare and progressive neurological disorder that currently has no cure, and treatment options are limited.
Clinical trials are an important way to advance our understanding of the disease and develop new treatments.
Some of the ongoing clinical trials for PSP include:
- Tau protein inhibitors: Tau protein is a key component of the abnormal brain deposits that are characteristic of PSP. Several clinical trials are currently investigating drugs that target tau protein and may slow the progression of the disease.
- Gene therapy: Gene therapy involves modifying a person's genetic material to treat or prevent disease. Several clinical trials are currently investigating gene therapies for PSP.
- Stem cell therapy: Stem cells have the ability to develop into different types of cells in the body, and may hold potential for regenerating damaged brain cells in individuals with PSP. Several clinical trials are currently investigating stem cell therapies for PSP.
- Cognitive and behavioral interventions: PSP can cause significant cognitive and behavioral changes, and clinical trials are currently investigating non-pharmacological interventions to address these symptoms.
Participating in a clinical trial can be a way for individuals with PSP to access new treatments and contribute to the development of new therapies. However, it's important to carefully consider the potential risks and benefits of participation, and discuss with a healthcare provider or clinical trial coordinator before making a decision.
Individuals with PSP and their families can find information about ongoing clinical trials through clinical trial registries such as ClinicalTrials.gov.